The major difference between patients with COPO who develop edema and those with signs
of" congestive failure" due to ischemic heart disease is that the systemic arteriolar resistance …

One possible intervention to interrupt the deleterious effects of the renin-angiotensin system
is suppression of angiotensin II (Ang II) formation by inhibition of angiotensin-converting …

Several studies have shown symptomatic and haemodynamic improvement after the
introduction of angiotensin converting enzyme inhibitors in patients with heart failure treated …

The effects of intravenous captopril and intravenous digoxin given separately and in
combination on rest and exercise hemodynamics were studied in 16 patients with severe …

The new, long acting converting enzyme inhibitor enalapril was given to 26 patients with
moderate to severe heart failure. In 23 cases the mean systolic blood pressure fell from 120 …

To determine if peripheral angiotensin II (Ang II) prejunctional receptors facilitating NE
release exist in humans, we used [3H] NE kinetic methodology to measure forearm NE …

Results from a large multicenter study and from the published literature suggest that
captopril can improve survival in patients with advanced heart failure. The survival status of …

Background Angiotensin-converting enzyme (ACE) inhibitors are established as first-line
therapy in chronic heart failure (CHF). However, conflicting results exist regarding the dose …

Although digitalis glycosides were introduced in the treatment of cardiac maladies> 200
years ago, controversy persists regarding the precise role of digoxin in any multidrug …

Ischemic heart disease is the most common underlying cause of congestive heart failure,
and thus aspirin (acetylsalicylic acid [ASA]) and angiotensin-converting enzyme (ACE) …